Related Experiment Video
Updated: Aug 6, 2026
10:25
Normothermic Cardiac Arrest and Cardiopulmonary Resuscitation: A Mouse Model of Ischemia-Reperfusion Injury
Published on: August 30, 2011
Anorexigen-related cardiopulmonary toxicity
1University of California, Los Angeles, Schools of Medicine and Nursing and Cedars-Sinai Medical Center, Los Angeles, USA.
Reviews in Cardiovascular Medicine
|November 29, 2002
Summary
Fenfluramine and dexfenfluramine, anorexigens, are linked to valvular heart disease and pulmonary hypertension. Their long-term cardiopulmonary effects and regression potential require ongoing patient surveillance and updated management guidelines.
Area of Science:
- Cardiology
- Pharmacology
- Pulmonology
Background:
- Fenfluramine and dexfenfluramine were withdrawn from the market due to concerns about adverse cardiopulmonary effects.
- Established links exist between these anorexigens and the development of valvular heart disease and primary pulmonary hypertension.
- The precise magnitude and prevalence of these deleterious effects remain undetermined years after market withdrawal.
Purpose of the Study:
- To assess the undetermined cardiopulmonary effects of fenfluramine and dexfenfluramine.
- To review the established links to valvular heart disease and primary pulmonary hypertension.
- To inform evolving management guidelines considering potential regression of valvular lesions.
Main Methods:
- Review of existing evidence on fenfluramine and dexfenfluramine.
- Analysis of established links to valvular heart disease and primary pulmonary hypertension.
- Consideration of data suggesting potential regression of drug-induced valvular lesions.
Main Results:
- The full extent and prevalence of cardiopulmonary damage from fenfluramine and dexfenfluramine are still not fully quantified.
- A clear association between these drugs and valvular heart disease and primary pulmonary hypertension is established.
- Emerging evidence suggests that valvular lesions may regress after drug cessation.
Conclusions:
- Despite market withdrawal, the long-term impact of fenfluramine and dexfenfluramine necessitates continued vigilance.
- Management strategies must adapt to the possibility of lesion regression.
- Close patient monitoring, including echocardiography, is recommended for affected individuals.
Related Concept Videos
01:21Acute Respiratory Failure-II
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
01:30Acute Respiratory Failure-III
Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without causing...
01:00Drug Toxicity: Overview
Drug toxicity quantifies the harm a compound causes to an organism, varying by dose and potentially impacting whole systems or specific organs like the liver. Toxic reactions may arise from venomous insect or spider bites, with effects ranging from mild symptoms to severe outcomes such as brain damage or death. Common forms of acute poisoning include ethanol intoxication and overdose of pain or fever medications, with substances like GHB and heroin being particularly lethal at doses close to...
01:24Drug Toxicity: Risk factors
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
01:24Drug Toxicity: Dose-Dependent Reactions
Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...
01:30Drug Toxicity: Allergic Reactions
Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial exposure to a...